CD161 antibody
- Known as:
- CD161 (anti-)
- Catalog number:
- orb100571
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- CD161 antibody
Related genes to: CD161 antibody
- Gene:
- KLRB1 NIH gene
- Name:
- killer cell lectin like receptor B1
- Previous symbol:
- NKR
- Synonyms:
- CD161, NKR-P1, NKR-P1A, hNKR-P1A, CLEC5B
- Chromosome:
- 12p13.31
- Locus Type:
- gene with protein product
- Date approved:
- 1998-01-16
- Date modifiied:
- 2016-10-05
Related products to: CD161 antibody
Related articles to: CD161 antibody
- In clear cell renal cell carcinoma (ccRCC), mast cell activation and angiogenesis are crucial for disease progression, with interactions occurring between these processes. The involvement of mast cell-related angiogenic characteristics in ccRCC is not yet fully elucidated. To address this gap, this study aims to clarify the biological role and prognostic significance of mast cell-mediated angiogenesis in ccRCC, and to examine its links to the tumor microenvironment and disease progression. - Source: PubMed
Publication date: 2026/06/27
Ji RanDai HaojieZhang XiKong WeiyuZhang JiajunWang YangWang JiajiaTang LeyuanCao XiaoyangLiu YiyangQin Chao - Sepsis and acute kidney injury (AKI) are life-threatening conditions often coexisting as sepsis-associated AKI (S-AKI). However, their shared molecular mechanisms and immune heterogeneity remain unclear. This study aims to identify robust diagnostic biomarkers applicable to both conditions and to elucidate their diverse immune microenvironments using integrated transcriptomic approaches. - Source: PubMed
Publication date: 2026/07/22
Huang YeqiuFei ShengnanHuang MinminHuang XinzhongLu Fei - Clinical decision-making for patients with community-acquired pneumonia (CAP) at risk of organ dysfunction and death is currently guided by clinical evaluation and scores. Every fifth patient with CAP requires admission to the ICU, with a subsequent high mortality; delayed admission to the ICU increases this risk. - Source: PubMed
Publication date: 2026/03/10
Kirsten HolgerWeis SebastianAhnert PeterWitzenrath MartinScicluna Brendon PKrohn KnutRade MichaelHorn FriedemannBertram CatharinaReiche KristinLöffler DennisBlumert ConnyJenner StefanSohn KaiNouailles GeraldineKiehntopf MichaelCreutz PetraRosolowski MaciejLoeffler MarkusSuttorp Norbert Scholz MarkusBauer Michael - Human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV + OPSCC) generally has favorable outcomes yet remains prone to late recurrence. Durable control likely depends on persistent tumor-specific CD8+ T cells, but their persistence and function in metastasis are poorly understood. - Source: PubMed
Publication date: 2026/07/26
Ishihara HiromasaShibata HirofumiMuraoka DaisukeDemachi-Okamura AyakoOkamoto TakanariMizuta RyoFukushima YasunoriSugita YusukeOgasawara AikoNishida ReinaBeppu ShintaroTerada HoshinoNishikawa DaisukeSuzuki HidenoriMasago KatsuhiroSasaki EiichiSakakura NoriakiYamaguchi RuiHanai NobuhiroOgawa TakenoriMatsushita Hirokazu - Neoadjuvant chemo-immunotherapy improves outcomes in resectable non-small cell lung cancer (NSCLC), but predicting postoperative recurrence remains challenging. While the precursor exhausted T cell (Texp) index offers prognostic value, the broader tumor immune microenvironment (TIME) contains untapped predictive potential. - Source: PubMed
Publication date: 2026/07/21
Ge JunTong XuesongWang XingxiaWang Jian